Tharimmune executes exclusive global licensing agreement for innovative clinical stage asset for chronic pruritis

Expects completion and topline data of a phase 2 clinical trial in chronic pruritis over approximately 12 months after aligning with fda on trial design seeking first approval in an orphan disease, pbc, for the treatment of chronic pruritis in which more than 70% of patients suffer from debilitating symptoms bridgewater, nj / accesswire / november 6, 2023 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announces the execution of an exclusive worldwide licensing agreement with avior inc. d/b/a avior bio, llc ("avior") to develop, market and commercialize a clinical-stage asset, av104 (to be renamed th104 and hereinafter referred to as th104). th104 has a dual mechanism of action affecting receptors known to suppress chronic, debilitating pruritis or "uncontrollable itching".
THAR Ratings Summary
THAR Quant Ranking